Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17227891 | 1.00 | GAA (0.41) | GAAMAOBCYP19A1PTGS2NFKB1 | |
| SCHEMBL25191819 | 1.00 | GAA (0.41) | GAAMAOBCYP19A1PTGS2NFKB1 | |
| SCHEMBL25264720 | 0.87 | NFKB1 (0.45) | GAAMAOBCYP19A1NFKB1NFKB2 | |
| SCHEMBL25188329 | 0.87 | NFKB1 (0.45) | GAAMAOBCYP19A1NFKB1NFKB2 | |
| SCHEMBL25194034 | 0.84 | CYP19A1 (0.38) | CYP19A1PTGS2NFKB1NFKB2RELA | |
| SCHEMBL3435780 | 0.84 | CYP19A1 (0.38) | CYP19A1PTGS2NFKB1NFKB2RELA | |
| SCHEMBL25187867 | 0.84 | CYP19A1 (0.38) | CYP19A1PTGS2NFKB1NFKB2RELA | |
| SCHEMBL25192428 | 0.82 | NFKB1 (0.40) | MAOBNFKB1NFKB2RELA | |
| SCHEMBL25192429 | 0.82 | NFKB1 (0.40) | MAOBNFKB1NFKB2RELA | |
| SCHEMBL25201323 | 0.81 | MAOB (0.40) | MAOBCYP19A1NFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952358-B2 | Flavan-3-ol analogs and anti-inflammatory activity | HONG KONG BAPTIST UNIVERSITY (CN) | 2024-04-09 | — | — | US | disclosed |
| US-20230159482-A1 | FLAVAN-3-OL ANALOGS AND ANTI-INFLAMMATORY ACTIVITY | HONG KONG BAPTIST UNIVERSITY (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20180099943-A1 | Catalytic Enantioselective Synthesis of 2-Aryl Chromenes and Related Phosphoramidite Ligands and Catalyst Compounds | NORTHWESTERN UNIVERSITY | 2018-04-12 | — | — | US | disclosed |
| US-9840487-B2 | Catalytic enantioselective synthesis of 2-aryl chromenes and related phosphoramidite ligands and catalyst compounds | NORTHWESTERN UNIVERSITY (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170217919-A1 | Catalytic Enantioselective Synthesis of 2-Aryl Chromenes and Related Phosphoramidite Ligands and Catalyst Compounds | NORTHWESTERN UNIVERSITY | 2017-08-03 | — | — | US | disclosed |
| US-9624190-B2 | Catalytic enantioselective synthesis of 2-aryl chromenes and related phosphoramidite ligands and catalyst compounds | NORTHWESTERN UNIVERSITY (US) | 2017-04-18 | — | — | US | disclosed |
| US-20160221982-A1 | Catalytic Enantioselective Synthesis of 2-Aryl Chromenes and Related Phosphoramidite Ligands and Catalyst Compounds | NORTHWESTERN UNIVERSITY | 2016-08-04 | — | — | US | disclosed |
| US-9309217-B2 | Catalytic enantioselective synthesis of 2-aryl chromenes and related phosphoramidite ligands and catalyst compounds | NORTHWESTERN UNIVERSITY (US) | 2016-04-12 | — | — | US | disclosed |
| US-20150315168-A1 | Catalytic Enantioselective Synthesis of 2-Aryl Chromenes and Related Phosphoramidite Ligands and Catalyst Compounds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217919-A1 | Catalytic Enantioselective Synthesis of 2-Aryl Chromenes and Related Phosphoramidite Ligands and Catalyst Compounds | PNP, PPA1, CDS2 | GAA 982/4885MAOB 927/4885CYP19A1 258/4885 |
| US-11952358-B2 | Flavan-3-ol analogs and anti-inflammatory activity | IL1A, IL6, IL1B | GAA 1562/4885MAOB 2663/4885CYP19A1 1986/4885 |
| US-20160221982-A1 | Catalytic Enantioselective Synthesis of 2-Aryl Chromenes and Related Phosphoramidite Ligands and Catalyst Compounds | PNP, PPA1, CDS2 | GAA 982/4885MAOB 927/4885CYP19A1 258/4885 |
| US-20150315168-A1 | Catalytic Enantioselective Synthesis of 2-Aryl Chromenes and Related Phosphoramidite Ligands and Catalyst Compounds | PNP, PPA1, CDS2 | GAA 982/4885MAOB 927/4885CYP19A1 258/4885 |
| US-20230159482-A1 | FLAVAN-3-OL ANALOGS AND ANTI-INFLAMMATORY ACTIVITY | IL1A, IL6, IL1B | GAA 1562/4885MAOB 2663/4885CYP19A1 1986/4885 |
| US-20180099943-A1 | Catalytic Enantioselective Synthesis of 2-Aryl Chromenes and Related Phosphoramidite Ligands and Catalyst Compounds | PNP, PPA1, CDS2 | GAA 982/4885MAOB 927/4885CYP19A1 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.